FDA Rejects Sanofi’s Multiple Sclerosis Drug Due to Safety and Efficacy Concerns
Sanofi's experimental oral BTK inhibitor tolebrutinib, intended for multiple sclerosis treatment, hit a regulatory setback with the FDA last month. The agency's detailed refusal highlights ongoing challenges in balancing drug safety and therapeutic proof in neuroimmune diseases.
FDA Complete Response on Sanofi MS Therapy
- The FDA issued a complete response letter rejecting Sanofi’s tolebrutinib for a form of multiple sclerosis.
- Key concerns included drug-related toxicities and ambiguous evidence of clinical benefit.
- This decision underscores the stringent regulatory scrutiny for new MS therapies.
Impact and Next Steps
- Sanofi will need to address the FDA's feedback, possibly through additional studies or data submissions.
- This scenario reflects the broader complexities in developing safe, effective treatments for autoimmune neurologic conditions.
Source: BioSpace
Join the BioIntel newsletter
Get curated biotech intelligence across AI, industry, innovation, investment, medtech, and policy—delivered to your inbox.